Merck Announces First-Quarter 2020 Financial Results
First-Quarter 2020 Worldwide Sales Were $12.1 Billion, an Increase of 11%; Excluding the Impact from Foreign Exchange, Sales Grew 13% KEYTRUDA Sales Grew 45% to $3.3 Billion; Excluding the Impact from Foreign Exchange, Sales Grew 46% Human Health Vaccines Sales Grew 14% to $2.2 Billion, Including the Effect of Timing; Excluding the Impact from Foreign Exchange, Sales Grew 16% First-Quarter 2020 GAAP EPS Was $1.26; First-Quarter Non-GAAP EPS Was $1.50 Company is Active in COVID-19-Related Antiviral and Vaccine Research Due to the Impact of COVID-19, Company Lowers 2020 Full-Year Revenue Range to be Between $46.1 Billion and $48.1 Billion, Including a Negative Impact from Foreign Exchange of Approximately 2.5% Due to the Impact of COVID-19, Company Lowers 2020 Full-Year GAAP EPS Range to be Between $4.12 and $4.32; Lowers 2020 Full-Year Non-GAAP EPS Range to be Between $5.17 and $5.37, Including a Negative Impact from Foreign Exchange of Approximately 3.5% Merck (NYSE: MRK), known as
https://www.merck.com/news/merck-announces-first-quarter-2020-financial-results/
From the military to Merck: Lessons in leadership
From jumping out of airplanes at Fort Bragg to helping launch the Army’s first-ever cyberspace forces, retired U.S. Army Colonel Martha VanDriel has never shied away from risk. Indeed, one of the greatest lessons she learned during her distinguished 26-year military career is the value of stretching beyond her comfort zone. It’s one of the […]
https://www.merck.com/stories/from-the-military-to-merck-lessons-in-leadership/
Pushing respiratory research forward
As a critical care pulmonologist, Dr. Stuart Green, vice president and therapeutic area head for late stage clinical development for respiratory and immunology at Merck Research Laboratories, has seen many of his patients fight to do what most people take for granted – breathing. The respiratory system is complicated and involves many different parts – […]
https://www.merck.com/stories/pushing-respiratory-research-forward/
Merck named to Forbes Just 100 list for “doing right by America”
We are excited to announce that Merck has been named #30 on Forbes and JUST Capital’s Just 100 list, a ranking of publicly traded American corporations that are leading the way with regard to the issues that Americans care about the most, including: worker pay and treatment, customer respect, environmental impact, community involvement, and ethical and diverse leadership. The […]
https://www.merck.com/stories/merck-named-to-forbes-just-100-list-for-doing-right-by-america/
I’m a cancer survivor. Now what?
Four years after her stage 3 melanoma diagnosis, Bethany G. shows no signs of disease and is proud to be a cancer survivor. “Being done and knowing that you’re finished is the most satisfying thing,” says Bethany, mother of two young girls. “It’s like this prize that you win for going through all of this.” […]
https://www.merck.com/stories/im-a-cancer-survivor-now-what/
Merck Asks Social Media Companies to do as Much as They Can to Stop Hate Speech, Racism and Discrimination; Merck to Stop Advertising on Facebook and Instagram, Assess Responses from Facebook and Monitor Actions
KENILWORTH, N.J. July 2, 2020 – Merck embraces our responsibility to be a force for good in the world – both through our medicines and vaccines, and through our broader actions to address inequities and to create an environment where all people are valued and respected. Diversity and inclusion are fundamental to the way Merck operates and to our mission to save and improve lives. As a company, we are committed to stopping hate speech, racism and discrimination wherever we can. As part of that commitment, we are calling on social media companies to do as much as they can to stop hate speech, racism and discrimination, and to create social media platforms that encourage sharing of accurate information. We have decided to stop our advertising on Facebook and Instagram. We are assessing the responses from Facebook and will be monitoring the actions they take, and we will do the same across other media platforms. Merck will continue to be a leader in advocating for diversity
https://www.merck.com/news/merck-asks-social-media-companies-to-do-as-much-as-they-can-to-stop-hate-speech-racism-and-discrimination-merck-to-stop-advertising-on-facebook-and-instagram-assess-responses-from-facebook-and-moni/
Answering your most pressing questions on antimicrobial resistance
As the world battles the COVID-19 pandemic, there is also the growing threat of antibiotic resistance – bacteria that are not killed by standard antibiotics and thrive in hospital settings. Dr. Black breaks down antibiotic resistance and Merck’s role in exploring how we fight bacteria in entirely new ways as we think beyond the pandemic. […]
https://www.merck.com/stories/answering-your-most-pressing-questions-on-antimicrobial-resistance/
Suppliers
Product service area Description Capital procurement Capital equipment Engineering & construction services Environmental & waste management Industrial maintenance MRO Engineering construction services Direct materials Production materials, packaging toll Energy Fuels and utilities Professional services Professional services HR, benefits & training Finance, banking & corporate insurance Site & commercial services Site services Travel & transportation Meeting […]
https://www.merck.com/company-overview/suppliers/
Inside Davos 2020: the World Economic Forum
There are critical public health threats all around the globe. From disease outbreaks like Ebola to the increasing number of moms who die during childbirth, the health issues facing our world are becoming more interconnected and harder to solve. “We can’t solve complex health challenges with medicines and vaccines alone, even though these tools are […]
https://www.merck.com/stories/inside-davos-2020-the-world-economic-forum/
U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for V114, Merck’s investigational 15-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in adults 18 years of age and older. The FDA set a Prescription Drug User Fee Act (PDUFA), or target action date, of July 18, 2021. The European Medicines Agency is also reviewing an application for licensure of V114 in adults. “Invasive pneumococcal disease in adults is on the rise in many countries, driven by highly-invasive serotypes including serotype 3, which is included in the currently licensed pneumococcal conjugate vaccine, as well as serotypes not included, such as serotypes 22F and 33F,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “Building on our nearly 40 years
https://www.merck.com/news/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older/
